{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:20:55Z","timestamp":1787847655519,"version":"build-2784847793"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Chronic neurological diseases are a major cause of mortality and morbidity in the world. With increasing life expectancy in the developing world, the incidence and prevalence of these diseases are predicted to rise even further. This has also contributed to an increase in disability-adjusted life years (DALYs) for noncommunicable diseases. Treatment for such diseases also poses a challenge with multiple genetic and epigenetic factors leading to a varied outcome. Personalization of treatment is one way that treatment outcome\/prognosis of disease can be improved, and pharmacogenomics plays a significant role in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology:<\/jats:title>\n                    <jats:p>This article reviewed the evidence pertaining to the association of genetic and epigenetic markers with major neurological disorders like multiple sclerosis (MS), Alzheimer's disease (AD), and Parkinson's disease (PD), which are a major source of burden among neurological disorders. Types of studies included are peer-reviewed original research articles from the PubMed database (1999\u20132018).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This study compiled data regarding specific genetic and epigenetic markers with a significant correlation between the clinical diagnosis of the disease and prognosis of therapy from 65 studies. In a single platform, this review highlights the clues to some vital questions, such as why interferon beta (IFN-\u03b2) therapy fails to improve symptoms in all MS patients? why cholinesterase inhibitors fail to improve cognitive impairment in a subset of people suffering from AD? or why some individuals on levodopa (L-DOPA) for PD suffer from side-effects ranging from dyskinesia to hallucination while others do not?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This article summarizes the genetic and epigenetic factors that may either require monitoring or help in deciding future pharmacotherapy in a patient suffering from MS, AD, and PD. As the health care system develops and reaches newer heights, we expect more and more of these biomarkers to be used as pharmacotherapeutic outcome indicators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.314522","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T01:30:50Z","timestamp":1619400650000},"page":"252-259","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Chronic Neurological Disorders"],"prefix":"10.4103","volume":"69","author":[{"given":"Sudhir Chandra","family":"Sarangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Sopory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KH","family":"Reeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20240907","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol"},{"key":"R2-4-20240907","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4103\/0028-3886.149365","article-title":"Epidemiology of neurological disorders in India: Review of background, prevalence and incidence of epilepsy, stroke, Parkinson's disease and tremors","volume":"62","author":"Gourie-Devi","year":"2014","journal-title":"Neurol India"},{"key":"R3-4-20240907","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: A systematic review and meta-analysis","volume":"3","author":"Hansen","year":"2008","journal-title":"Clin Interv Aging"},{"key":"R4-4-20240907","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinson's disease: A review","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs Aging"},{"key":"R5-4-20240907","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1212\/WNL.0000000000000036","article-title":"Assessing treatment response to interferon- : Is there a role for MRI?","volume":"82","author":"Dobson","year":"2014","journal-title":"Neurology"},{"key":"R6-4-20240907","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.neuron.2011.01.002","article-title":"Anti-A\u03b2 therapeutics in Alzheimer's disease: The need for a paradigm shift","volume":"69","author":"Golde","year":"2011","journal-title":"Neuron"},{"key":"R7-4-20240907","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1756285613488434","article-title":"Sex and gender issues in multiple sclerosis","volume":"6","author":"Harbo","year":"2013","journal-title":"Ther Adv Neurol Disord"},{"key":"R8-4-20240907","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/brain\/awn301","article-title":"Genotype\u2013Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures","volume":"132","author":"Okuda","year":"2009","journal-title":"Brain"},{"key":"R9-4-20240907","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/nan.12165","article-title":"The influence of HLA-DRB1* 15 on motor cortical pathology in multiple sclerosis","volume":"41","author":"Yates","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R10-4-20240907","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jneuroim.2010.10.038","article-title":"Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments","volume":"233","author":"Gross","year":"2011","journal-title":"J Neuroimmunol"},{"key":"R11-4-20240907","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2217\/pgs.16.2","article-title":"HLA genes as modifiers of response to IFN-\u03b2-1a therapy in relapsing-remitting multiple sclerosis","volume":"17","author":"Mazdeh","year":"2016","journal-title":"Pharmacogenomics"},{"key":"R12-4-20240907","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/00023210-200923050-00003","article-title":"Neutralizing antibodies to interferon-\u03b2 and other immunological treatments for multiple sclerosis","volume":"23","author":"Deisenhammer","year":"2009","journal-title":"CNS Drugs"},{"key":"R13-4-20240907","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/tpj.2011.14","article-title":"Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-\u03b2 therapy in multiple sclerosis patients","volume":"12","author":"Weber","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"R14-4-20240907","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1172\/JCI22833","article-title":"Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS","volume":"115","author":"Villar","year":"2005","journal-title":"J Clin Invest"},{"key":"R15-4-20240907","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/1352458510371961","article-title":"Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands","volume":"16","author":"Bosca","year":"2010","journal-title":"Mult Scler J"},{"key":"R16-4-20240907","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24345","article-title":"Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab","volume":"77","author":"Villar","year":"2015","journal-title":"Ann Neurol"},{"key":"R17-4-20240907","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"R18-4-20240907","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1196\/annals.1423.067","article-title":"Mechanism of action of IFN-beta in the treatment of multiple sclerosis: A special reference to CD73 and adenosine","volume":"1110","author":"Airas","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"R19-4-20240907","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.clinthera.2010.10.006","article-title":"A meta-analysis of the efficacy and tolerability of interferon-\u03b2 in multiple sclerosis, overall and by drug and disease type","volume":"32","author":"Nikfar","year":"2010","journal-title":"Clin Ther"},{"key":"R20-4-20240907","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1186\/1742-2094-9-140","article-title":"Elevated type I interferon-like activity in a subset of multiple sclerosis patients: Molecular basis and clinical relevance","volume":"9","author":"Hundeshagen","year":"2012","journal-title":"J Neuroinflammation"},{"key":"R21-4-20240907","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1468-1331.2004.01102.x","article-title":"IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis","volume":"12","author":"Wergeland","year":"2005","journal-title":"Eur J Neurol"},{"key":"R22-4-20240907","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.yexmp.2013.12.010","article-title":"SIRT1 is decreased during relapses in patients with multiple sclerosis","volume":"96","author":"Tegla","year":"2014","journal-title":"Exp Mol Pathol"},{"key":"R23-4-20240907","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12017-014-8335-5","article-title":"miR26a modulates Th17\/Treg balance in the EAE model of multiple sclerosis by targeting IL6","volume":"17","author":"Zhang","year":"2015","journal-title":"Neuromolecular Med"},{"key":"R24-4-20240907","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.gene.2014.04.069","article-title":"miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing\u2013remitting multiple sclerosis","volume":"544","author":"Honardoost","year":"2014","journal-title":"Gene"},{"key":"R25-4-20240907","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1755-8794-7-26","article-title":"Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-\u03b2","volume":"7","author":"De Felice","year":"2014","journal-title":"BMC Med Genomics"},{"key":"R26-4-20240907","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ncl.2007.03.008","article-title":"Alzheimer's disease and mild cognitive impairment","volume":"25","author":"Kelley","year":"2007","journal-title":"Neurol Clin"},{"key":"R27-4-20240907","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"R28-4-20240907","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000051232","article-title":"Responder characteristics to a single oral dose of cholinesterase inhibitor: A double-blind placebo-controlled study with tacrine in Alzheimer patients","volume":"12","author":"Almkvist","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R29-4-20240907","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/BF03256262","article-title":"Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease","volume":"11","author":"Cacabelos","year":"2007","journal-title":"Mol Diagn Ther"},{"key":"R30-4-20240907","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/WAD.0b013e318299d096","article-title":"The effect of APOE \u03b54 allele on cholinesterase inhibitors in patients with Alzheimer disease","volume":"28","author":"Wang","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"R31-4-20240907","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jalz.2016.06.006","article-title":"Therapeutic strategies for the treatment of tauopathies: Hopes and challenges","volume":"12","author":"Khanna","year":"2016","journal-title":"Alzheimers Dement"},{"key":"R32-4-20240907","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1385\/JMN:19:3:267","article-title":"Cdk5 as a drug target for the treatment of Alzheimer's disease","volume":"19","author":"Lau","year":"2002","journal-title":"J Mol Neurosci"},{"key":"R33-4-20240907","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.tips.2017.03.011","article-title":"A brief overview of tauopathy: Causes, consequences, and therapeutic strategies","volume":"38","author":"Orr","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"R34-4-20240907","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2353\/ajpath.2007.061178","article-title":"Lithium reduces tau phosphorylation but not A\u03b2 or working memory deficits in a transgenic model with both plaques and tangles","volume":"170","author":"Caccamo","year":"2007","journal-title":"Am J Pathol"},{"key":"R35-4-20240907","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3233\/JAD-150437","article-title":"Lithium as a treatment for Alzheimer's disease: A systematic review and meta-analysis","volume":"48","author":"Matsunaga","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"R36-4-20240907","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000329514","article-title":"Pharmacogenetic study on the effect of rivastigmine on PS2 and APOE genes in Iranian Alzheimer patients","volume":"1","author":"Zamani","year":"2011","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"R37-4-20240907","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/7420796","article-title":"Antidiabetic drugs in Alzheimer's disease: Mechanisms of action and future perspectives","volume":"2017","author":"Femminella","year":"2017","journal-title":"J Diabetes Res"},{"key":"R38-4-20240907","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","article-title":"Inflammation as a central mechanism in Alzheimer's disease","volume":"4","author":"Kinney","year":"2018","journal-title":"Alzheimer's Dement Transl Res Clin Interv"},{"key":"R39-4-20240907","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2318-5-2","article-title":"Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: The MIRAGE Study","volume":"5","author":"Yip","year":"2005","journal-title":"BMC Geriatr"},{"key":"R40-4-20240907","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/00003495-200363080-00001","article-title":"Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease","volume":"63","author":"Launer","year":"2003","journal-title":"Drugs"},{"key":"R41-4-20240907","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0029-1237423","article-title":"Epigenetics: Definition, mechanisms and clinical perspective","volume":"27","author":"Dupont","year":"2009","journal-title":"Semin Reprod Med"},{"key":"R42-4-20240907","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1515\/CCLM.2005.200","article-title":"Interactions between folate and aging for carcinogenesis","volume":"43","author":"Choi","year":"2005","journal-title":"Clin Chem Lab Med"},{"key":"R43-4-20240907","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jalz.2005.06.001","article-title":"Reduced risk of Alzheimer's disease with high folate intake: The Baltimore longitudinal study of aging","volume":"1","author":"Corrada","year":"2005","journal-title":"Alzheimers Dement"},{"key":"R44-4-20240907","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3233\/JAD-2011-110080","article-title":"Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression","volume":"26","author":"Govindarajan","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"R45-4-20240907","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3233\/JAD-2009-1134","article-title":"Dysregulation of histone acetylation in the APP\/PS1 mouse model of Alzheimer's disease","volume":"18","author":"Francis","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"R46-4-20240907","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/npp.2009.197","article-title":"Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease","volume":"35","author":"Kilgore","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R47-4-20240907","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/nn.3782","article-title":"Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease","volume":"17","author":"Lunnon","year":"2014","journal-title":"Nat Neurosci"},{"key":"R48-4-20240907","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/nn.3786","article-title":"Alzheimer's disease: Early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci","volume":"17","author":"De Jager","year":"2014","journal-title":"Nat Neurosci"},{"key":"R49-4-20240907","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fnbeh.2015.00347","article-title":"Epigenetic alterations in Alzheimer's disease","volume":"9","author":"Sanchez-Mut","year":"2015","journal-title":"Front Behav Neurosci"},{"key":"R50-4-20240907","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Curr Med Chem"},{"key":"R51-4-20240907","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mad.2006.11.013","article-title":"Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: A pharmacogenomic approach","volume":"128","author":"Candore","year":"2007","journal-title":"Mech Ageing Dev"},{"key":"R52-4-20240907","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/hipo.22245","article-title":"Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease","volume":"24","author":"Sanchez-Mut","year":"2014","journal-title":"Hippocampus"},{"key":"R53-4-20240907","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1038\/tp.2012.55","article-title":"Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients","volume":"2","author":"Rao","year":"2012","journal-title":"Transl Psychiatry"},{"key":"R54-4-20240907","doi-asserted-by":"crossref","first-page":"e895","DOI":"10.1371\/journal.pone.0000895","article-title":"DNA Methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons","volume":"2","author":"Siegmund","year":"2007","journal-title":"PLoS One"},{"key":"R55-4-20240907","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10849","article-title":"An epigenetic blockade of cognitive functions in the neurodegenerating brain","volume":"483","author":"Gr\u00e4ff","year":"2012","journal-title":"Nature"},{"key":"R56-4-20240907","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jns.2011.05.031","article-title":"Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium","volume":"307","author":"McGuire","year":"2011","journal-title":"J Neurol Sci"},{"key":"R57-4-20240907","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00228-009-0658-z","article-title":"Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients","volume":"65","author":"Liu","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R58-4-20240907","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1212\/WNL.53.7.1425","article-title":"Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD","volume":"53","author":"Oliveri","year":"1999","journal-title":"Neurology"},{"key":"R59-4-20240907","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00008571-200002000-00006","article-title":"Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease","volume":"10","author":"Makoff","year":"2000","journal-title":"Pharmacogenetics"},{"key":"R60-4-20240907","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/mds.20245","article-title":"Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting \u201csleep attacks.\u201d","volume":"19","author":"Rissling","year":"2004","journal-title":"Mov Disord"},{"key":"R61-4-20240907","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/humu.20039","article-title":"Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1","volume":"23","author":"Neville","year":"2004","journal-title":"Hum Mutat"},{"key":"R62-4-20240907","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0404.2004.00315.x","article-title":"The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease","volume":"110","author":"Bialecka","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"R63-4-20240907","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/mds.23805","article-title":"Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease","volume":"27","author":"de Lau","year":"2012","journal-title":"Mov Disord"},{"key":"R64-4-20240907","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JPD-130186","article-title":"Levodopa in the treatment of Parkinson's disease: Current status and new developments","volume":"3","author":"Salat","year":"2013","journal-title":"J Parkinsons Dis"},{"key":"R65-4-20240907","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.parkreldis.2013.10.017","article-title":"Dopa-decarboxylase gene polymorphisms affect the motor response to l-dopa in Parkinson's disease","volume":"20","author":"Devos","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"R66-4-20240907","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12017-011-8163-9","article-title":"Next-generation sequencing reveals regional differences of the \u03b1-synuclein methylation state independent of Lewy body disease","volume":"13","author":"de Boni","year":"2011","journal-title":"Neuromolecular Med"},{"key":"R67-4-20240907","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/mds.26319","article-title":"L-dopa increases \u03b1 -synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro","volume":"30","author":"Schmitt","year":"2015","journal-title":"Mov Disord"},{"key":"R68-4-20240907","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1126\/science.aaf3934","article-title":"\u03b22-Adrenoreceptor is a regulator of the \u03b1-synuclein gene driving risk of Parkinson's disease","volume":"357","author":"Mittal","year":"2017","journal-title":"Science"},{"key":"R69-4-20240907","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fnagi.2018.00283","article-title":"Clinical heterogeneity among LRRK2 variants in Parkinson's disease: A meta-analysis","volume":"10","author":"Shu","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"R70-4-20240907","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10142-011-0246-z","article-title":"Emerging roles of epigenetic mechanisms in Parkinson's disease","volume":"11","author":"Habibi","year":"2011","journal-title":"Funct Integr Genomics"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.314522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:26:39Z","timestamp":1787844399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.314522"}},"subtitle":["Genetic and Epigenetic Markers for Monitoring of Pharmacotherapy"],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.314522","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}